Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study

Table 2

Association analysis between PFS of the 68 elderly patients with advanced NSCLC and baseline characteristic subgroups in univariate analysis and multivariate Cox analysis.

Baseline characteristics	Median PFS (95%CI)	(univariate analysis)	Multivariate analysis
			HR (95%CI)
Age
<72	3.5 (2.43–4.57)	0.53
≥72	3.1 (2.39–3.81)
Gender
Male	3.1 (2.39–3.81)	0.32
Female	3.9 (2.61–5.19)
ECOG performance status score
0–1	4.2 (2.31–6.09)	0.02	0.69 (0.41–0.91)	0.03
2	2.8 (2.11–3.49)
Pathological staging
IIIb	3.9 (2.85–4.95)	0.44
IV	3.1 (2.18–4.02)
Smoking status
Nonsmoker/former smoker	3.9 (2.91–4.89)	0.53
Smoker	3.5 (2.62–4.38)
Histology
Adenocarcinoma	3.5 (2.41–4.59)	0.42
Squamous cell carcinoma	3.1 (2.31–3.89)
Lines of PD-1 blockade therapy
Second line	3.9 (2.75–5.05)	0.67
Third line or more	3.5 (2.48–4.52)
Number of metastatic lesions
≤3	3.9 (2.38–5.42)	0.01	0.61 (0.37–0.83)	0.02
>3	2.3 (1.42–3.18)
History of targeted drug therapy
Yes	3.9 (3.01–4.79)	0.42
No	3.5 (2.46–4.54)
PD-1 blockades
Camrelizumab	3.1 (2.08–4.12)	0.36
Sintilimab	3.5 (2.81–4.19)
Pembrolizumab	3.9 (2.71–5.09)
Nivolumab	3.0 (2.03–3.97)

NSCLC, non-small cell lung cancer; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; PD-1, programmed cell death protein 1; CI, confidence interval; HR: hazard ratio.